An Introduction to Headache Disorders
Headache disorders, most common debilitating disorders in the world, are responsible for almost three quarters of all neurological-related disabilities. Primary headache disorders include migraine, tension headache and cluster headache. The most common type of secondary headache is medication-overuse headache. The past decade has seen substantial breakthroughs in headache management. New therapeutic strategies target the CGRP ligand or receptor, transforming the treatment paradigm for migraine, and proving useful against cluster headache. Another novel strategy are ditans, a new class of acute treatments that target the serotonin 5-HT1F receptor.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Headache Disorders Content
Pre-filled Pen for Anti-calcitonin Gene-related Peptide Migraine Therapy
European Neurological Review. 2020;15(1):11-2 DOI: https://doi.org/10.17925/ENR.2020.15.1.11
Despite the fact that migraine is the most prevalent neurological disorder worldwide, it remains under-diagnosed and under-treated in more than half of all patients.1 In the past decade, the development of monoclonal antibodies capable of blocking either calcitonin gene-related peptide (CGRP) or its receptor have transformed the management of migraine.2 At present, fremanezumab (Ajovy®) is […]
The Upper Nasal Space—A Novel Delivery Route Ideal for Central Nervous System Drugs
US Neurology. 2020:16(1):25–31 DOI: https://doi.org/10.17925/USN.2020.16.1.25
Treatment of acute central nervous system (CNS) conditions requires effective drugs that can provide rapid onset of effect, consistent blood levels, ease-of-use for patient or caregiver, and acceptable tolerability. Solid oral dosage forms account for up to 75% of prescriptions from healthcare providers.1 They are less expensive and easier to manufacture than drug–device combination products, offer […]
Peter Goadsby, EAN 2020 – Visual Snow Syndrome
Delighted to interview our valued Editorial Board member Peter Goadsby (King’s College Hospital, London, UK), who shared his expert insights on visual snow syndrome and related updates presented at the 1st Virtual EAN Congress. Questions 1. What are the clinical features and spectrum of severity of visual snow syndrome, and how was it first identified? […]
Uwe Reuter, EAN 2020 – Characteristics of the HER-MES trial in episodic and chronic migraine
Uwe Reuter (Charité Universitätsmedizin Berlin, Germany) talks to us about the first head-to-head randomized, double-blind, double-dummy trial of erenumab and topiramate for the prevention of episodic and chronic migraine (ClinicalTrials.gov Identifier: NCT03828539). Questions 1. What are the unmet needs in the treatment of episodic migraine? (0:05) 2. Could you tell us a little about the […]
Hans-Christoph Diener, EAN 2020 – Chronic Migraine and Medication-Overuse Headache – PROMISE-2
Hans-Christoph Diener (Medical Faculty of the University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, Essen, Germany) talks to us about unmet needs in the treatment of chronic migraine and medication-overuse headache, and shares expert insight on the PROMISE-2 trial, which evaluated the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal […]
Stefan Evers, EAN 2020 – Miscellaneous Idiopathic Headache Disorders
A pleasure catching up with our European Editorial Board member Stefan Evers (University of Münster, Germany). He spoke to us about miscellaneous idiopathic headache disorders, the topic of his presentation in the ‘Integrative Treatment of Idiopathic Headache Disorders’ session. Questions 1. What is covered by the term ‘miscellaneous idiopathic headache disorders’? (0:05) 2. What are […]
Stephanie J Nahas, EAN 2020 – Anti-CGRP mAb Efficacy in Patients ≥60 With Episodic/Chronic Migraine
Stephanie J Nahas (Thomas Jefferson University, Jefferson Headache Center, Philadelphia, PA, USA) kindly took the time to discuss with us pooled findings from phase 3 randomised controlled trials with fremanezumab, an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody treatment, specifically in older patients (≥60 years) with episodic or chronic migraine. Questions 1. How does the clinical […]
Rational Prescribing with an Individualized Approach to Therapy for the Prevention of Migraine
US Neurology. 2020:16(1):15–8 DOI: https://doi.org/10.17925/USN.2020.16.1.15
Although preventive treatment has been a mainstay of migraine treatment for decades, it still remains vastly underutilized.1,2 In recent years, however, the profusion of new treatments for migraine has expanded the therapeutic arsenal for the preventive treatment of migraine. Clinical care pathway for the prevention of migraine John Rothrock When selecting the appropriate preventive therapy, […]
The Group Visit Model—A Promising Option for Clinical Care Delivery in Patients with Chronic Migraine
US Neurology. 2020:16(1):19–24 DOI: https://doi.org/10.17925/USN.2020.16.1.19
The medical group visit model is an innovative mode of care delivery that has gained popularity with clinicians, as it offers more options for chronic care management, with the added possibility of improving financial productivity. Group medical visits were initially developed in the 1970s in an effort to offer high-quality medical care with additional elements […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!